Skip to main content
Premium Trial:

Request an Annual Quote

Jonathan Seaton

Illumina has appointed Jonathan Seaton as senior VP for corporate and business development. In this role, Seaton will be responsible for global business development activities, including strategic commercial deals, mergers and acquisitions, licensing, and partnerships. He joins Illumina from Becton Dickinson, where he was VP and head of strategy and business development for the Life Sciences segment. He previously held leadership roles at Hoffman-La Roche, Roche Tissue Diagnostics, LS9, and several consulting firms and investment banks.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.